stoxline Quote Chart Rank Option Currency Glossary
Epizyme, Inc. (EPZM)
1.47  0 (0%)    12-31 19:00
Open: 1.49
High: 1.4993
Volume: 0
Pre. Close: 1.47
Low: 1.47
Market Cap: 0(M)
Technical analysis
2022-11-18 4:20:17 PM
Short term     
Mid term     
Targets 6-month :  1.73 1-year :  1.75
Resists First :  1.48 Second :  1.49
Pivot price 1.47
Supports First :  1.47 Second :  1.22
MAs MA(5) :  1.47 MA(20) :  1.47
MA(100) :  1.47 MA(250) :  1.47
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  0 D(3) :  0
RSI RSI(14): 60.7
52-week High :  3.59 Low :  0.41
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ EPZM ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 88 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.5 - 1.51 1.51 - 1.52
Low: 1.45 - 1.46 1.46 - 1.47
Close: 1.46 - 1.47 1.47 - 1.48
Company Description

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. As of August 11, 2022, Epizyme, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..

Headline News

Mon, 27 Jun 2022
Ipsen to Acquire Epizyme - Growth in Oncology - Ipsen

Thu, 02 Jun 2022
Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory ... - Business Wire

Thu, 27 Jan 2022
Epizyme Announces Pricing of Public Offering of Common Stock - Business Wire

Wed, 26 Jan 2022
Epizyme Announces Proposed Public Offering of Common Stock - Business Wire

Sat, 11 Dec 2021
Epizyme Presents Preclinical Data and Phase 1/1b Trial Design on the Company's SETD2 Inhibitor, EZM0414, at the ... - Business Wire

Thu, 04 Nov 2021
Epizyme Receives Fast Track Designation from U.S. FDA and Announces Initiation of Phase 1/1b Study of its Novel ... - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 104 (M)
Shares Float 133 (M)
Held by Insiders 0.5 (%)
Held by Institutions 90.3 (%)
Shares Short 5,490 (K)
Shares Short P.Month 10,390 (K)
Stock Financials
EPS -2.3
EPS Est Next Qtrly -0.68
EPS Est This Year -2.36
EPS Est Next Year -2.45
Book Value (p.s.) 1.46
Profit Margin 0 %
Operating Margin -582.2 %
Return on Assets (ttm) -39 %
Return on Equity (ttm) -352.4 %
Qtrly Rev. Growth 14 %
Gross Profit (p.s.) 0.17
Sales Per Share 0.37
EBITDA (p.s.) -2.11
Qtrly Earnings Growth 0 %
Operating Cash Flow -210 (M)
Levered Free Cash Flow -112 (M)
Stock Valuations
PE Ratio -0.65
PEG Ratio -0.1
Price to Book value 1
Price to Sales 3.96
Price to Cash Flow -0.73
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android